EODData

ASX, SPL: Starpharma Holdings Ltd.

15 Oct 2026
LAST:

0.7500

CHANGE:
 0.05
OPEN:
0.8000
HIGH:
0.8050
ASK:
0.0980
VOLUME:
2.42M
CHG(%):
6.25
PREV:
0.8000
LOW:
0.7300
BID:
0.0940
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 260.80000.80500.73000.75002.42M
14 Oct 260.83000.83000.80000.80001.15M
13 Oct 260.84500.84750.82500.83002.21M
12 Oct 260.83000.86000.83000.85002.59M
09 Oct 260.83500.85000.83000.84502.44M
08 Oct 260.83000.84500.82250.83501.29M
07 Oct 260.81000.84500.81000.83001.87M
06 Oct 260.82000.82000.79500.81502.64M
05 Oct 260.80500.82000.80500.81001.88M
02 Oct 260.82000.82000.78000.80004.01M

PROFILE

Name:Starpharma Holdings Ltd.
About:Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067
Website:https://starpharma.com
ISIN:AU000000SPL0
FIGI:BBG000BW3JT0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:-47.98 
Forward P/E:187.78 
PEG Ratio:187.78 
Price to Sales:32.00 
Price to Book:25.61 
Profit Margin:-0.59 
Operating Margin:-5.84 
Return on Assets:-0.21 
Return on Equity:-0.46 
EPS Ratio:-0.02 
Revenue:12.67M 
Shares:477.05M 
Market Cap:357.79M 

TECHNICAL INDICATORS

MA5:0.828.7%
MA10:0.828.9%
MA20:0.829.1%
MA50:0.773.0%
MA100:0.750.6%
MA200:0.6319.7%
RSI14:35.00 
WPR14:-100.00 
MTM14:-0.07
ROC14:-0.09 
ATR:0.04 
Week High:0.8614.7%
Week Low:0.732.7%
Month High:0.8816.7%
Month Low:0.7319.7%
Year High:0.8816.7%
Year Low:0.26188.5%
Volatility:56.87